Daily Respiratory Research Analysis
Three impactful studies span mechanisms, modeling, and bedside prediction in respiratory medicine. A preclinical study identifies KDM6B as a mechanistic link by which intermittent hypoxia from obstructive sleep apnea exacerbates pulmonary fibrosis, while a computational investigation suggests high-flow nasal cannula may generate higher airway pressures in acute hypoxemic respiratory failure than previously assumed. A clinical cohort shows high-sensitivity troponin T independently predicts extuba
Summary
Three impactful studies span mechanisms, modeling, and bedside prediction in respiratory medicine. A preclinical study identifies KDM6B as a mechanistic link by which intermittent hypoxia from obstructive sleep apnea exacerbates pulmonary fibrosis, while a computational investigation suggests high-flow nasal cannula may generate higher airway pressures in acute hypoxemic respiratory failure than previously assumed. A clinical cohort shows high-sensitivity troponin T independently predicts extubation failure in COVID-19 ARDS, enabling more objective weaning risk stratification.
Research Themes
- Mechanistic pathways linking sleep-disordered breathing to pulmonary fibrosis
- Airway pressure physiology during high-flow nasal cannula support in AHRF
- Biomarker-based risk stratification for extubation in severe respiratory failure
Selected Articles
1. The histone demethylase KDM6B links obstructive sleep apnea to idiopathic pulmonary fibrosis.
KDM6B expression is elevated in human IPF lungs and experimental models, and intermittent hypoxia further amplifies its expression and profibrotic programs. Pharmacologic inhibition of KDM6B attenuated fibrosis, reduced myofibroblast activation and migration, and downregulated NOX4 and oxidative stress, positioning KDM6B as a tractable target linking OSA to IPF progression.
Impact: This study provides a mechanistic bridge between sleep-disordered breathing and pulmonary fibrosis and identifies a druggable epigenetic target (KDM6B) with in vivo efficacy. It opens a new therapeutic avenue for IPF, a disease with limited options.
Clinical Implications: If translated, KDM6B inhibition could mitigate fibrosis progression in IPF, particularly in patients with coexisting OSA. It also strengthens the rationale for aggressive diagnosis and treatment of OSA in fibrotic lung disease.
Key Findings
- KDM6B expression is increased in IPF lungs, bleomycin-treated mice, and TGF-β1–stimulated myofibroblasts.
- Intermittent hypoxia exacerbates fibrosis and myofibroblast activation and further upregulates KDM6B in vivo and in vitro.
- Pharmacologic inhibition of KDM6B reduces fibrosis, fibroblast activation/migration, and NOX4-driven oxidative stress.
Methodological Strengths
- Multiple complementary models (human tissue, bleomycin mice, dual-hit intermittent hypoxia models, and in vitro assays).
- Convergent mechanistic readouts (myofibroblast activation, NOX4 expression, oxidative stress) and pharmacologic inhibition.
Limitations
- Preclinical models; clinical efficacy and safety of KDM6B inhibition remain untested.
- The specificity of KDM6B targeting and potential off-target epigenetic effects need careful evaluation.
Future Directions: Translate KDM6B inhibition into early-phase trials in fibrotic lung disease (with and without OSA), define patient selection biomarkers (e.g., KDM6B/NOX4 signatures), and explore combinatorial strategies with antifibrotics and OSA treatment.
Obstructive sleep apnea (OSA) is increasingly recognized for its link to idiopathic pulmonary fibrosis (IPF), though the underlying mechanisms remain poorly understood. Histone lysine demethylase 6B (KDM6B) may either prevent or promote organ fibrosis, but its specific role in IPF is yet to be clarified. This study aimed to investigate the function and mechanisms of KDM6B in IPF and the exacerbating effects of OSA. We assessed KDM6B levels in lung tissues from IPF patients, IPF mouse models, and a dual-hit model combining OSA-associated intermittent hypoxia (IH) with bleomycin (BLM) or TGF-β1. We evaluated pulmonary fibrosis, myofibroblast activation, and oxidative stress. KDM6B levels were elevated in lung tissues from IPF patients and BLM-treated mice, as well as in TGF-β1-stimulated myofibroblasts. Importantly, IH significantly worsened BLM-induced pulmonary fibrosis and TGF-β1-induced myofibroblast activation, further amplifying KDM6B expression both in vivo and in vitro. Inhibition of KDM6B reduced pulmonary fibrosis and decreased fibroblast activation and migration in IPF and dual-hit models. Mechanistically, KDM6B inhibition led to decreased NOX4 expression and reduced oxidative stress. KDM6B plays a critical role in promoting pulmonary fibrosis and mediating the exacerbating effects of OSA on this condition. Our findings identify KDM6B as a novel potential therapeutic target for IPF.
2. Airway pressures generated by high flow nasal cannula in patients with acute hypoxemic respiratory failure: a computational study.
A high-fidelity cardiopulmonary model calibrated to healthy data and extended to AHRF physiology suggests that HFNC can generate higher mean airway pressures in diseased lungs than expected from healthy-subject experiments, especially with the mouth closed. This underscores potential benefits (recruitment) and risks (overdistension) and motivates close monitoring and patient-specific titration.
Impact: Challenges extrapolation from healthy-subject HFNC physiology to AHRF and provides quantitative rationale for individualized HFNC titration. Could influence monitoring strategies and thresholds to prevent overdistension.
Clinical Implications: Clinicians should monitor lung mechanics (compliance, work of breathing) and consider mouth position when titrating HFNC flow, recognizing that delivered PEEP may be higher in AHRF than assumed. Bedside trials directly measuring airway pressures in AHRF are warranted.
Key Findings
- Model reproduced HFNC airway pressures in healthy volunteers across flow rates and mouth positions.
- Simulated AHRF physiology (alveolar consolidation/collapse) increased mean airway pressures for the same HFNC settings compared with healthy states.
- Closed-mouth breathing further elevated airway pressures, highlighting a risk of overdistension without recruitment.
Methodological Strengths
- High-fidelity mechanistic modeling with calibration against human volunteer data.
- Systematic exploration of disease states (varying degrees of consolidation/collapse) and mouth position effects.
Limitations
- No direct patient airway pressure measurements; findings are model-based.
- Heterogeneity of AHRF etiologies and patient interfaces not fully captured.
Future Directions: Prospective clinical studies to measure airway pressures and lung mechanics during HFNC in AHRF across severities and mouth positions; development of bedside decision-support integrating modeling and real-time physiology.
INTRODUCTION AND OBJECTIVES: High flow nasal cannula (HFNC) therapy is an increasingly popular mode of non-invasive respiratory support for the treatment of patients with acute hypoxemic respiratory failure (AHRF). Previous experimental studies in healthy subjects have established that HFNC generates flow-dependent positive airway pressures, but no data is available on the levels of mean airway pressure (mP MATERIALS AND METHODS: We developed a high-fidelity mechanistic computational model of the cardiopulmonary system during HFNC therapy using data from healthy subjects, and then measured the mP RESULTS: When calibrated to represent normal lung physiology in healthy subjects, our model recapitulates the airway pressures produced by HFNC at different flow rates in healthy volunteers who were breathing normally, with their mouths closed or open. When different amounts of alveolar consolidation/collapse are implemented in the model to reflect the pathophysiology of AHRF, the mP CONCLUSIONS: Our results suggest that the airway pressures produced by HFNC in patients with AHRF could be higher than is currently assumed based on experimental data from healthy subjects, particularly in patients whose mouths remain closed. Higher levels of PEEP could be beneficial if they lead to alveolar recruitment and improved lung compliance, but could cause alveolar overdistension if they do not, motivating the close monitoring of the effects of HFNC on lung mechanics. Further clinical studies are warranted to directly measure the airway pressures produced by HFNC in patients with different severities of AHRF.
3. The prognostic role of cardiac and inflammatory biomarkers in extubation failure in patients with COVID-19 acute respiratory distress syndrome.
In 297 C-ARDS patients, extubation failure occurred in 21.5%. Day-of-extubation Hs-TnT, NT-proBNP, and PCT correlated with failure, but Hs-TnT remained independently predictive after adjustment (adjusted OR 1.38). Combined elevation of Hs-TnT (≥14 ng/mL) and PCT (≥0.25 ng/mL) identified a very high-risk group (46% failure) versus 13% when both normal.
Impact: Provides a simple, immediately available biomarker (Hs-TnT) to augment decision-making for extubation in severe respiratory failure, with a pragmatic combined-risk stratification using PCT.
Clinical Implications: In C-ARDS, measuring Hs-TnT on extubation day can inform readiness and post-extubation monitoring intensity; patients with concurrent Hs-TnT and PCT elevations may benefit from delayed extubation, closer surveillance, or prophylactic noninvasive support.
Key Findings
- Extubation failure rate was 21.5% among 297 C-ARDS patients.
- Hs-TnT (adjusted OR 1.38) independently predicted extubation failure after adjusting for age, ventilation duration, and SOFA.
- Dual elevation of Hs-TnT (≥14 ng/mL) and PCT (≥0.25 ng/mL) marked a 46% failure risk vs 13% when both were normal.
Methodological Strengths
- Clear endpoint definition (reintubation or death within 7 days) and multivariable adjustment for key confounders.
- Clinically accessible biomarkers measured at a standardized time point (day of extubation).
Limitations
- Single-center retrospective design limits generalizability and residual confounding.
- Study confined to C-ARDS; applicability to non-COVID ARDS needs validation.
Future Directions: External validation across centers and inclusion of non-COVID ARDS; integration of Hs-TnT into predictive models alongside physiological weaning indices and imaging to guide extubation decisions.
BACKGROUND: Extubation failure is associated with an increased morbidity, emphasizing the need to identify factors to further optimize extubation practices. The role of biomarkers in the prediction of extubation failure is currently limited. The aim of this study was to investigate the prognostic value of cardiac (N-terminal pro-B-type natriuretic peptide (NT-proBNP), High-sensitivity Troponin T (Hs-TnT)) and inflammatory biomarkers (Interleukin-6 (IL-6) and Procalcitonin (PCT)) for extubation failure in patients with COVID-19 Acute Respiratory Distress Syndrome (C-ARDS). MATERIALS AND METHODS: In this single-center retrospective cohort study, patient characteristics and laboratory measurements were extracted from electronic medical records. Patients were eligible for inclusion if they were extubated after mechanical ventilation. The primary endpoint was extubation failure, defined as the need for reintubation or death within the next seven days after extubation, regardless of whether post-extubation respiratory support was used. Uni- and multivariable logistic regression was performed to investigate the association between biomarkers and extubation failure. Biomarkers were log RESULTS: Of the 297 patients included, 21.5% experienced extubation failure. In univariable analysis, NT-proBNP (OR 1.24, 95% CI 1.06-1.47), Hs-TnT (OR 1.72, 95% CI 1.37-2.19) and PCT (OR 1.38, 95% CI 1.16-1.65) measured on the day of extubation were significantly associated with extubation failure. After multivariable adjustment for clinical variables (age, duration of mechanical ventilation, SOFA score), Hs-TnT was the only biomarker that was independently associated with extubation failure (adjusted OR 1.38, 95% CI 1.02-1.90). Patients with both elevated Hs-TnT (≥ 14 ng/mL) and elevated PCT (≥ 0.25 ng/mL) carried the highest risk of extubation failure (46%), while in patients with normal Hs-TnT and PCT values, only 13% experienced extubation failure. CONCLUSIONS: Hs-TnT, NT-proBNP and PCT measured on the day of extubation are associated with extubation failure in mechanically ventilated patients with C-ARDS. Since Hs-TnT is the only biomarker that is independently associated with extubation failure, Hs-TnT could offer additional objective measures for assessing readiness for extubation. Future studies should focus on an integrative approach of biomarkers combined with relevant clinical factors to predict extubation failure.